251 related articles for article (PubMed ID: 21285984)
1. Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease.
Kang BH; Tavecchio M; Goel HL; Hsieh CC; Garlick DS; Raskett CM; Lian JB; Stein GS; Languino LR; Altieri DC
Br J Cancer; 2011 Feb; 104(4):629-34. PubMed ID: 21285984
[TBL] [Abstract][Full Text] [Related]
2. Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer.
Kang BH; Siegelin MD; Plescia J; Raskett CM; Garlick DS; Dohi T; Lian JB; Stein GS; Languino LR; Altieri DC
Clin Cancer Res; 2010 Oct; 16(19):4779-88. PubMed ID: 20876793
[TBL] [Abstract][Full Text] [Related]
3. Feasibility and safety of targeting mitochondria for cancer therapy - preclinical characterization of gamitrinib, a first-in-class, mitochondriaL-targeted small molecule Hsp90 inhibitor.
Hayat U; Elliott GT; Olszanski AJ; Altieri DC
Cancer Biol Ther; 2022 Dec; 23(1):117-126. PubMed ID: 35129069
[TBL] [Abstract][Full Text] [Related]
4. Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer.
Leav I; Plescia J; Goel HL; Li J; Jiang Z; Cohen RJ; Languino LR; Altieri DC
Am J Pathol; 2010 Jan; 176(1):393-401. PubMed ID: 19948822
[TBL] [Abstract][Full Text] [Related]
5. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.
Raina K; Rajamanickam S; Singh RP; Deep G; Chittezhath M; Agarwal R
Cancer Res; 2008 Aug; 68(16):6822-30. PubMed ID: 18701508
[TBL] [Abstract][Full Text] [Related]
6. Tumor Necrosis Factor Receptor-associated Protein 1 (TRAP1) Mutation and TRAP1 Inhibitor Gamitrinib-triphenylphosphonium (G-TPP) Induce a Forkhead Box O (FOXO)-dependent Cell Protective Signal from Mitochondria.
Kim H; Yang J; Kim MJ; Choi S; Chung JR; Kim JM; Yoo YH; Chung J; Koh H
J Biol Chem; 2016 Jan; 291(4):1841-1853. PubMed ID: 26631731
[TBL] [Abstract][Full Text] [Related]
7. 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.
Lin Z; Peng R; Li Z; Wang Y; Lu C; Shen Y; Wang J; Shi G
Int J Mol Med; 2015 Aug; 36(2):424-32. PubMed ID: 26059743
[TBL] [Abstract][Full Text] [Related]
8. Murine prostate cancer inhibition by dietary phytochemicals--curcumin and phenyethylisothiocyanate.
Barve A; Khor TO; Hao X; Keum YS; Yang CS; Reddy B; Kong AN
Pharm Res; 2008 Sep; 25(9):2181-9. PubMed ID: 18437538
[TBL] [Abstract][Full Text] [Related]
9. Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model.
Li X; Yokoyama NN; Zhang S; Ding L; Liu HM; Lilly MB; Mercola D; Zi X
Oncotarget; 2015 Dec; 6(39):41809-24. PubMed ID: 26497688
[TBL] [Abstract][Full Text] [Related]
10. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90.
Kang BH; Plescia J; Song HY; Meli M; Colombo G; Beebe K; Scroggins B; Neckers L; Altieri DC
J Clin Invest; 2009 Mar; 119(3):454-64. PubMed ID: 19229106
[TBL] [Abstract][Full Text] [Related]
11. Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model.
Raghow S; Kuliyev E; Steakley M; Greenberg N; Steiner MS
Cancer Res; 2000 Aug; 60(15):4093-7. PubMed ID: 10945615
[TBL] [Abstract][Full Text] [Related]
12. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
[TBL] [Abstract][Full Text] [Related]
13. Gene signatures distinguish stage-specific prostate cancer stem cells isolated from transgenic adenocarcinoma of the mouse prostate lesions and predict the malignancy of human tumors.
Mazzoleni S; Jachetti E; Morosini S; Grioni M; Piras IS; Pala M; Bulfone A; Freschi M; Bellone M; Galli R
Stem Cells Transl Med; 2013 Sep; 2(9):678-89. PubMed ID: 23884639
[TBL] [Abstract][Full Text] [Related]
14. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
15. Targeting HSP90 attenuates angiotensin II-induced adventitial remodelling via suppression of mitochondrial fission.
Huang G; Cong Z; Wang X; Yuan Y; Xu R; Lu Z; Wang X; Qi J
Cardiovasc Res; 2020 Apr; 116(5):1071-1084. PubMed ID: 31346611
[TBL] [Abstract][Full Text] [Related]
16. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer?
Siegelin MD
Cancer Lett; 2013 Jun; 333(2):133-46. PubMed ID: 23376257
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis.
Bono AV; Pannellini T; Liberatore M; Montironi R; Cunico SC; Cheng L; Sasso F; Musiani P; Iezzi M
Anal Quant Cytol Histol; 2010 Jun; 32(3):136-45. PubMed ID: 20701066
[TBL] [Abstract][Full Text] [Related]
19. Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model.
Ru P; Steele R; Nerurkar PV; Phillips N; Ray RB
Cancer Prev Res (Phila); 2011 Dec; 4(12):2122-30. PubMed ID: 21911444
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
